Cost-Effectiveness Analysis of Treatment with Liposomal Amphotericin B versus Conventional Amphotericin B in Organ or Bone Marrow Transplant Recipients with Systemic Mycoses
- 1 December 1992
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 2 (6) , 500-508
- https://doi.org/10.2165/00019053-199202060-00008
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A RANDOMIZED TRIAL OF CYCLOSPORINE AND PREDNISOLONE VERSUS CYCLOSPORINE, AZATHIOPRINE, AND PREDNISOLONE IN PRIMARY CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1992
- Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug TherapiesPharmacoEconomics, 1992
- Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patientsJournal of Antimicrobial Chemotherapy, 1991
- Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trialJournal of Antimicrobial Chemotherapy, 1991
- Pancreatic transplantation using enteric exocrine diversion: the Stockholm experience with 117 cases.1990
- Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival.1990
- HEPATIC TRANSPLANTATION IN EUROPEThe Lancet, 1987
- Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.Journal of Clinical Oncology, 1987
- Opportunities for improving the cost-effectiveness of antihypertensive treatmentThe American Journal of Medicine, 1986
- Cost-Effectiveness of Interventions to Prevent or Treat Coronary Heart DiseaseAnnual Review of Public Health, 1985